Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) - Total Liabilities

Latest as of June 2025: CN¥222.24 Million CNY ≈ $32.52 Million USD

Based on the latest financial reports, Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has total liabilities worth CN¥222.24 Million CNY (≈ $32.52 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Shandong Keyuan Pharmaceutical Co. Ltd. (301281) net asset momentum to track the company's year-over-year net asset growth rate.

Shandong Keyuan Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2021–2024)

This chart illustrates how Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Shandong Keyuan Pharmaceutical Co. Ltd. to measure how efficiently the company converts operating cash flow to free cash.

Shandong Keyuan Pharmaceutical Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of Shandong Keyuan Pharmaceutical Co. Ltd. A ranked by their total liabilities.

Company Country Total Liabilities
Citychamp Dartong Co Ltd
SHG:600067
China CN¥10.26 Billion
Mühlbauer Holding AG
XETRA:MUB
Germany €315.43 Million
Ningbo Jianan Electronics Co Ltd
SHE:300880
China CN¥510.23 Million
Atlanta Braves Holdings, Inc. Series A Common Stock
NASDAQ:BATRA
USA $8.16 Billion
Everlight Chemical Industrial Corp
TW:1711
Taiwan NT$4.36 Billion
Diversified Royalty Corp
TO:DIV
Canada CA$323.66 Million
First Sensor AG
F:SIS
Germany €42.02 Million
Chengdu M&S Electronics Technology Co Ltd
SHG:688311
China CN¥587.29 Million

Liability Composition Analysis (2021–2024)

This chart breaks down Shandong Keyuan Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Shandong Keyuan Pharmaceutical Co. Ltd. .

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.55 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.16 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.14 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Shandong Keyuan Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2024)

The table below shows the annual total liabilities of Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥192.87 Million
≈ $28.22 Million
+38.83%
2023-12-31 CN¥138.93 Million
≈ $20.33 Million
+5.20%
2022-12-31 CN¥132.06 Million
≈ $19.32 Million
+2.75%
2021-12-31 CN¥128.52 Million
≈ $18.81 Million
--

About Shandong Keyuan Pharmaceutical Co. Ltd. A

SHE:301281 China Drug Manufacturers - General
Market Cap
$561.75 Million
CN¥3.84 Billion CNY
Market Cap Rank
#11496 Global
#3207 in China
Share Price
CN¥35.45
Change (1 day)
+5.04%
52-Week Range
CN¥26.26 - CN¥58.05
All Time High
CN¥59.70
About

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more